FREDERICK, Md., April 15, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.? (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announces attendance at Interphex 2024 showcasing new innovations. Interphex 2024 provides an opportunity for a wide range of biotechnology industry leaders to discover SteraMist's groundbreaking iHP technology and will be held in New York City on April 16-18, 2024.

SteraMist will present its iHP technology through live demonstrations, highlighting the significant advancements it provides to the pharmaceutical industry. Experts will be available to provide insights and discuss tailored solutions to integrate SteraMist iHP disinfection technology. Explore the latest innovations from SteraMist, including the NV+ and the SteraMist Integrated System (SIS), the newest additions to the product line.

"Interphex stands out as one of the year's most significant pharmaceutical conferences. We are thrilled to unveil the NV+ and the SIS at this event, as these products meet and exceed the current disinfection demands of the life sciences industry," remarks Elissa J. Shane, COO of TOMI. "We eagerly anticipate engaging with partners, clients, and prospective clients as we continue to make significant strides within the life science industry."

Don't miss the chance to connect, exchange professional insights, and discover how SteraMist can enhance your decontamination protocols. Join us at SteraMist, booth 2445.

TOMI? Environmental Solutions, Inc.: Innovating for a safer world?  

TOMI? Environmental Solutions, Inc. (NASDAQ: TOMZ ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology ? (BIT?) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT? solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP?) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments.

For additional information, please visit https://www.steramist.com or contact us at [email protected]

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to corporate service contracts with partners. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.

INVESTOR RELATIONS CONTACT:

John Nesbett/Rosalyn Christian

IMS Investor Relations

[email protected]